Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI115649

Immunoglobulin light chain variable region gene sequences for human antibodies to Haemophilus influenzae type b capsular polysaccharide are dominated by a limited number of V kappa and V lambda segments and VJ combinations.

E E Adderson, P G Shackelford, R A Insel, A Quinn, P M Wilson, and W L Carroll

Division of Infectious Diseases, Washington University School of Medicine, St. Louis Children's Hospital, Missouri 63110.

Find articles by Adderson, E. in: PubMed | Google Scholar

Division of Infectious Diseases, Washington University School of Medicine, St. Louis Children's Hospital, Missouri 63110.

Find articles by Shackelford, P. in: PubMed | Google Scholar

Division of Infectious Diseases, Washington University School of Medicine, St. Louis Children's Hospital, Missouri 63110.

Find articles by Insel, R. in: PubMed | Google Scholar

Division of Infectious Diseases, Washington University School of Medicine, St. Louis Children's Hospital, Missouri 63110.

Find articles by Quinn, A. in: PubMed | Google Scholar

Division of Infectious Diseases, Washington University School of Medicine, St. Louis Children's Hospital, Missouri 63110.

Find articles by Wilson, P. in: PubMed | Google Scholar

Division of Infectious Diseases, Washington University School of Medicine, St. Louis Children's Hospital, Missouri 63110.

Find articles by Carroll, W. in: PubMed | Google Scholar

Published March 1, 1992 - More info

Published in Volume 89, Issue 3 on March 1, 1992
J Clin Invest. 1992;89(3):729–738. https://doi.org/10.1172/JCI115649.
© 1992 The American Society for Clinical Investigation
Published March 1, 1992 - Version history
View PDF
Abstract

The immune repertoire to Haemophilus influenzae type b capsular polysaccharide (Hib PS) appears to be dominated by certain light chain variable region genes (IgVL). In order to examine the molecular basis underlying light chain bias, IgVL genes have been cloned from a panel of heterohybridomas secreting human anti-Hib PS (antibody) (anti-Hib PS Ab). One hybridoma, representative of the predominant serum clonotype of anti-Hib PS Ab in older children and adults following immunization or Hib infection, uses a V kappa II segment identical to the germline gene A2, and a JK3 segment. A second kappa hybridoma uses a member of the V kappa I family and a JK4 segment. Four lambda antibodies, all cross-reactive with the structurally related antigen Escherichia coli K100 PS, use V lambda VII segments which are 96-98% homologous to one another, and may originate from a single germline gene. Two additional lambda antibodies, not K100-cross-reactive, are encoded by members of the V lambda II family. All lambda antibodies use highly homologous J lambda 2 or J lambda 3 segments. The VJ joints of all lambda antibodies and the V kappa II-encoded antibody are notable for the presence of an arginine codon, suggesting an important role in antigen binding. Although more complex than heavy chain variable region gene usage, a significant portion of serum anti-Hib PS Ab is likely to be encoded by a limited number of V kappa and V lambda segments and VJ combinations, which may be selectively expressed during development, or following antigen exposure.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 729
page 729
icon of scanned page 730
page 730
icon of scanned page 731
page 731
icon of scanned page 732
page 732
icon of scanned page 733
page 733
icon of scanned page 734
page 734
icon of scanned page 735
page 735
icon of scanned page 736
page 736
icon of scanned page 737
page 737
icon of scanned page 738
page 738
Version history
  • Version 1 (March 1, 1992): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts